HER2+ Gastric Cancer Therapy Market Set for Steady Growth by 2033 | DataM Intelligence

The HER2+ gastric cancer therapy market will grow at a 5.8% CAGR through 2033, driven by novel therapies and fresh U.S. and Japan investments.

CALIFORNIA, CA, UNITED STATES, July 25, 2025 /EINPresswire.com/ -- Human epidermal growth factor receptor 2–positive (HER2+) gastric cancer represents a critical subset of gastric malignancies amenable to targeted therapies. According to DataM Intelligence analysis, the global HER2+ gastric cancer therapeutics market was valued at approximately USD 1.2 billion in 2024 and is projected to reach USD 2 billion by 2033, registering a compound annual growth rate (CAGR) of 5.8%. This growth reflects increasing adoption of HER2-targeted antibodies, antibody–drug conjugates (ADCs), and emerging bispecific constructs that improve patient outcomes and survival rates.

Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://www.datamintelligence.com/download-sample/her2-gastric-cancer-market

Therapeutic Landscape of HER2+ Gastric Cancer

Established Therapies

Trastuzumab combined with chemotherapy remains the first-line standard of care, extending median overall survival by several months. Second-line ADCs, most notably trastuzumab deruxtecan have demonstrated superior progression free survival (PFS), catalyzing their rapid uptake in clinical practice.

Emerging Modalities

Next-generation approaches include:
• Bispecific Antibodies: Molecules engaging both HER2 and T cell receptors to enhance anti tumor immunity.
• TKI Combinations: Small-molecule inhibitors targeting downstream HER2 signaling pathways, often combined with immunotherapies.
• Cell Therapies: Early stage CAR T constructs engineered to recognize HER2+ gastric tumor antigens.

Regional Outlook on HER2+ Gastric Cancer Therapy Market

North America
North America accounts for nearly 40% of global revenue, driven by strong clinical trial networks, rapid regulatory approvals, and high per patient therapy costs. The U.S. leads in adoption of ADCs and bispecifics, supported by broad insurance coverage.

Asia-Pacific & Japan
Asia-Pacific is the fastest growing region, with Japan at the forefront. Japan’s ageing population and national cancer initiatives are accelerating HER2+ gastric cancer detection and treatment. According to DataM Intelligence, Japan’s segment grew from USD 180 million in 2024 to USD 195 million in 2025, reflecting an 8.3% year on year rise aligned with new product launches and expanded screening.

Recent Investments in HER2+ Gastric Cancer Therapy Market

United States
• June 2025: AstraZeneca committed USD 85 million to upgrade its Cambridge, Massachusetts facility, increasing output capacity for bispecific anti HER2 antibodies under development.

Japan
• April 2025: Daiichi Sankyo invested ¥18 billion (USD 130 million) to establish a state of the art ADC research center in Kanagawa Prefecture, focusing on next gen HER2 targeted therapies.
• June 2025: Eisai entered a ¥12 billion (USD 85 million) co development deal with Biogen in Tokyo to advance a novel HER2 directed bispecific antibody through Phase I/II trials.

Industry Collaborations & Pipeline Highlights
• Roche & Chugai extended their collaboration to optimize trastuzumab deruxtecan dosing regimens for Japanese patients, initiating a bridging study in Q2 2025.
• Seattle Genetics (now Seagen) & AbbVie launched a joint Phase II trial combining an experimental HER2 ADC with PD 1 blockade in refractory gastric cancer.
• Zymeworks published Phase I data for ZW 19—a biparatopic HER2 ADC—showing manageable safety and encouraging tumor response rates.

Looking for in-depth insights? Grab the full report: https://www.datamintelligence.com/buy-now-page?report=her2-gastric-cancer-market

Latest News of USA (2025)

In July 2025, the U.S. FDA granted Fast Track designation to Seagen’s ZW 19 in combination with pembrolizumab for second-line HER2+ gastric cancer, based on early-phase data demonstrating a 35% objective response rate. Concurrently, the National Cancer Institute awarded USD 50 million to fund biomarker-driven trials evaluating HER2 low gastric tumors.

Latest News of Japan (2025)
In May 2025, Japan’s PMDA issued Sakigake designation to Daiichi Sankyo’s novel ADC program targeting HER2 mutations prevalent in East Asian populations, accelerating its review timeline. In parallel, the Japanese Society of Gastroenterology published updated screening guidelines to include reflex HER2 testing for all newly diagnosed gastric cancer patients.

Challenges & Future Outlook

Challenges
• Resistance Mechanisms: Tumor heterogeneity and emerging HER2 negative clones limit long term efficacy.
• Cost & Access: High therapy prices and infrastructure gaps in emerging markets remain barriers.

Future Outlook

Advances in bispecific antibodies, combination regimens, and personalized cell therapies promise to overcome resistance and improve durability. Ongoing investments and regulatory initiatives in the U.S. and Japan will accelerate pipeline maturation, paving the way for more effective, accessible HER2+ gastric cancer treatments by 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Related Reports:

Gastrointestinal Cancer Drugs Market

Gastrointestinal Therapeutics Market

Sai Kumar
DataM Intelligence 4market Research LLP
+1 877-441-4866
sai.k@datamintelligence.com
Visit us on social media:
LinkedIn
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.